Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1

MONDO:0100083

This is an autosomal dominant disorder caused by mutations in the RUNX1 gene and is characterized by mild to moderate thrombocytopenia, platelet functional and/or ultrastructural defects and a predisposition to hematologic malignancies, most often AML and MDS, and less frequently T-ALL.

Also known as: FPD/AML syndrome, FPS/AML syndrome, Familial Platelet Disorder with Associated Myeloid Malignancy, familial platelet disorder with associated myeloid malignancy, familial platelet syndrome with predisposition to acute myelogenous leukaemia, familial platelet syndrome with predisposition to acute myelogenous leukemia, hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1, FPDMM

41 clinical trials for this condition and its sub-types, 5 tagged with Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Hereditary thrombocytopenia and hematologic cancer predisposition syndrome (5)

Including sub-types (41) Tagged with Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 (5)

Trials to join now! 4 Not yet recruiting 1

Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1

Where it sits in the disease tree

Could a low-dose drug boost blood health in rare platelet disorder?

Could a cancer drug fix a bleeding disorder and prevent leukemia?

Scientists track rare gene variant to unlock blood disorder mysteries

First step toward a cure? stem cell harvesting trial launches for rare platelet disorder